At a glance
ClinicalIndex Comparison RecordN/ACompleted· 964 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Phase 4 Study to Demonstrate the Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.
In Brief
An observational study for Heart Failure (HF). Completed, enrolled 964 participants across 1 site.
Detailed Summary
This aim of the study is to investigate the prognostic usefulness of AdreView™ imaging to identify those subjects with New York Heart Association (NYHA) Class II or III HF who will die during 60 months of follow-up from the date of administration of AdreView™ in prior studies MBG311, MBG312, or MBG312C (hereafter included in MBG312).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure (HF)
CountriesUnited States
CollaboratorsH2O Clinical LLC, Quintiles, Inc.
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
First PostedApr 2014
Primary CompletionDec 2014
Study CompletionApr 2016
TodayJul 2026
First PostedApr 30, 2014
Enrollment StartFeb 1, 2014
Primary CompletionDec 1, 2014
Study CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.2 years ago